Cancer; chemotherapy; immunotherapy; radiotherapy

Alliance Parisienne des Instituts de Recherche en Cancérologie

Pôle hospitalier Universitaire Cancer (PHUC) (PHUC)

Pôle hospitalier Universitaire Cancer (PHUC)

Informations générales

Référence projet : 11-PHUC-0002
Etablissement Coordinateur : COMUE Sorbonne Paris Cité
Région du projet : Île-de-France
Discipline : 5 - Bio Med

Aide de l'ANR 10 000 000 euros
Investissement couvrant la période de décembre 2012 à décembre 2017

Résumé de soumission

The Paris Alliance of Cancer Research Institutes (PACRI) has been created to spearhead basic, translational and clinical cancer research in the Greater Paris area, which concentrates more than half of the National research output in oncology. PACRI, which is composed by Institut Curie, Gustave Roussy (GR), Institut Universitaire en Hématologie/St. Louis, and University Paris Descartes, has been starting its activities in mid-2013. PACRI has established and consolidated research platforms dedicated to (epi)genetics, bioinformatics, screening and cell biology, as well as to tumor immunology. PACRI has built a network of cell biology facilties allowing for phenotyping screening of anticancer drug effects on cells expressing fluorescent biosensors. In addition, PACRI has created a networked “mouse cancer clinics” designed to monitor drug effects on both xenotransplanted primary human cancers and genetically defined, oncogene-driven murine cancers. PACRI has begun the exploration of selected breakthrough concepts designed to treat cancer, with an emphasis on the integration of genomic and epigenomic data and cell biology studies for drug screening. PACRI is also confirming the hypothesis that, to be successful, cytotoxic and targeted cancer therapies require an anticancer immune response, which in turn is determined by the gut microbiota. In synthesis, PACRI is improving the efficiency of existing – ever more integrated – cancer research facilities, hence making the Greater Paris area (Ile-de-France) a prominent and highly visible center in translational and clinical oncology.



L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.

Liens utiles